Results 161 to 170 of about 160,408 (307)

Multi‐omics–driven precision medicine

open access: yesiMeta, EarlyView.
Multi‐omics‐driven precision medicine (MODPM) provides a multiscale, continuously learnable framework that integrates genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiome profiles, and clinical data. Powered by artificial intelligence and foundation models, MODPM enables cross‐modal representation learning, contextual modeling ...
Huibo Li   +20 more
wiley   +1 more source

Immune Checkpoint Inhibitors Induce Intestinal Epithelial Injury and a Senescence‐Like Phenotype

open access: yesiNew Medicine, EarlyView.
ICI treatment promotes the infiltration of activated immune cells into the intestinal mucosa. This inflammatory microenvironment is associated with significant epithelial injury, characterized by the disruption of the epithelial barrier, the depletion of specialized secretory cell lineages, and the induction of a premature senescence phenotype ...
Juan Wang   +7 more
wiley   +1 more source

Trained immunity: An unexplored component of IBD pathogenesis. [PDF]

open access: yesInflamm Bowel Dis
Doulberis M   +3 more
europepmc   +1 more source

Insight into IBD

open access: yesThe American Journal of Nursing, 1994
openaire   +2 more sources

Air Pollution Quinones Impair Intestinal Barrier Integrity and Endoplasmic Reticulum in Differentiated Caco‐2 Cells

open access: yesJournal of Applied Toxicology, EarlyView.
ABSTRACT Particulate matter (PM) is a major global health threat, linked to millions of deaths annually. Beyond inhalation, PM components reach the gastrointestinal tract through the mucociliary escalator or contaminated food and water. Among PM's organic fraction, redox‐active quinones such as 1,2‐naphthoquinone (NQ) and 9,10‐phenanthrenequinone (PQ ...
Franco Cervellati   +6 more
wiley   +1 more source

Use of Biosimilars in Pediatric Inflammatory Bowel Disease: An Updated Position Statement of the Pediatric IBD Porto Group of ESPGHAN

open access: yes, 2019
TBiologic therapies have changed the outcome of both adult and pediatric patients with Inflammatory Bowel Disease (IBD). In September 2013, the first biosimilar of infliximab was introduced into the pharmaceutical market.
Paediatric IBD Porto group of ESPGHAN
core  

Home - About - Disclaimer - Privacy